Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 94.32%
March 31, 2026 87.63%
December 31, 2025 58.07%
September 30, 2025 53.70%
June 30, 2025 -64.72%
March 31, 2025 -5.82%
December 31, 2024 -24.96%
September 30, 2024 -39.24%
June 30, 2024 -209.9%
March 31, 2024 -76.10%
December 31, 2023 -109.0%
September 30, 2023 -71.32%
June 30, 2023 -43.94%
March 31, 2023 -28.71%
December 31, 2022 -37.15%
September 30, 2022 83.69%
June 30, 2022 -51.87%
March 31, 2022 51.88%
December 31, 2021 22.26%
September 30, 2021 16.98%
June 30, 2021 -8.47%
March 31, 2021 47.06%
December 31, 2020 28.67%
September 30, 2020 44.08%
June 30, 2020 50.99%
Date Value
March 31, 2020 54.34%
December 31, 2019 9.36%
September 30, 2019 21.00%
June 30, 2019 49.08%
March 31, 2019 34.41%
December 31, 2018 66.03%
September 30, 2018 52.77%
June 30, 2018 59.06%
March 31, 2018 65.07%
December 31, 2017 80.06%
September 30, 2017 67.37%
June 30, 2017 69.05%
March 31, 2017 70.58%
December 31, 2016 69.11%
September 30, 2016 69.46%
June 30, 2016 67.46%
March 31, 2016 64.93%
December 31, 2015 63.95%
September 30, 2015 68.77%
June 30, 2015 59.31%
March 31, 2015 58.53%
December 31, 2014 47.96%
September 30, 2014 54.54%
June 30, 2014 0.00%
March 31, 2014 0.00%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Repligen Corp. 49.25%
AC Immune SA 0.00%
Amgen, Inc. 72.08%
Geron Corp. 94.94%
Neurocrine Biosciences, Inc. 95.87%

Gross Profit Margin (Quarterly) Related Metrics